Logo image of DAWN

DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Fundamental Analysis

NASDAQ:DAWN - Nasdaq - US23954D1090 - Common Stock - Currency: USD

7.93  +0.31 (+4.07%)

After market: 7.93 0 (0%)

Fundamental Rating

4

Taking everything into account, DAWN scores 4 out of 10 in our fundamental rating. DAWN was compared to 566 industry peers in the Biotechnology industry. While DAWN has a great health rating, there are worries on its profitability. DAWN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DAWN has reported negative net income.
In the past year DAWN has reported a negative cash flow from operations.
In the past 5 years DAWN always reported negative net income.
DAWN had a negative operating cash flow in each of the past 5 years.
DAWN Yearly Net Income VS EBIT VS OCF VS FCFDAWN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of DAWN (-16.39%) is better than 81.63% of its industry peers.
DAWN has a Return On Equity of -18.99%. This is amongst the best in the industry. DAWN outperforms 87.10% of its industry peers.
Industry RankSector Rank
ROA -16.39%
ROE -18.99%
ROIC N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
DAWN Yearly ROA, ROE, ROICDAWN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

With an excellent Gross Margin value of 95.98%, DAWN belongs to the best of the industry, outperforming 94.70% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for DAWN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DAWN Yearly Profit, Operating, Gross MarginsDAWN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

DAWN does not have a ROIC to compare to the WACC, probably because it is not profitable.
DAWN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DAWN has been increased compared to 5 years ago.
There is no outstanding debt for DAWN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DAWN Yearly Shares OutstandingDAWN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DAWN Yearly Total Debt VS Total AssetsDAWN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

DAWN has an Altman-Z score of 4.46. This indicates that DAWN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of DAWN (4.46) is better than 79.68% of its industry peers.
There is no outstanding debt for DAWN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.46
ROIC/WACCN/A
WACC9.96%
DAWN Yearly LT Debt VS Equity VS FCFDAWN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

DAWN has a Current Ratio of 7.66. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.66, DAWN is doing good in the industry, outperforming 72.97% of the companies in the same industry.
DAWN has a Quick Ratio of 7.61. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of DAWN (7.61) is better than 72.97% of its industry peers.
Industry RankSector Rank
Current Ratio 7.66
Quick Ratio 7.61
DAWN Yearly Current Assets VS Current LiabilitesDAWN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.21% over the past year.
EPS 1Y (TTM)25.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

DAWN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.59% yearly.
Based on estimates for the next years, DAWN will show a very strong growth in Revenue. The Revenue will grow by 41.20% on average per year.
EPS Next Y10.61%
EPS Next 2Y25%
EPS Next 3Y31.09%
EPS Next 5Y27.59%
Revenue Next Year27.25%
Revenue Next 2Y44.13%
Revenue Next 3Y47.77%
Revenue Next 5Y41.2%

3.3 Evolution

DAWN Yearly Revenue VS EstimatesDAWN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
DAWN Yearly EPS VS EstimatesDAWN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DAWN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DAWN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DAWN Price Earnings VS Forward Price EarningsDAWN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DAWN Per share dataDAWN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as DAWN's earnings are expected to grow with 31.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25%
EPS Next 3Y31.09%

More info and screens

0

5. Dividend

5.1 Amount

DAWN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (5/2/2025, 8:00:01 PM)

After market: 7.93 0 (0%)

7.93

+0.31 (+4.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2025-02-25/amc
Earnings (Next)05-06 2025-05-06/bmo
Inst Owners94.33%
Inst Owner Change0.02%
Ins Owners2.14%
Ins Owner Change0.09%
Market Cap803.71M
Analysts82.67
Price Target29.87 (276.67%)
Short Float %21.81%
Short Ratio14.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.9%
Min EPS beat(2)-73.33%
Max EPS beat(2)11.53%
EPS beat(4)2
Avg EPS beat(4)6.31%
Min EPS beat(4)-73.33%
Max EPS beat(4)93.47%
EPS beat(8)5
Avg EPS beat(8)4.26%
EPS beat(12)7
Avg EPS beat(12)-0.25%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-6.71%
Min Revenue beat(2)-16.43%
Max Revenue beat(2)3.01%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.92%
PT rev (3m)-19.64%
EPS NQ rev (1m)-2.97%
EPS NQ rev (3m)-36.61%
EPS NY rev (1m)-12.8%
EPS NY rev (3m)-39.29%
Revenue NQ rev (1m)-2.55%
Revenue NQ rev (3m)-5.38%
Revenue NY rev (1m)-5.8%
Revenue NY rev (3m)-4.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.13
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.65
EV/EBITDA N/A
EPS(TTM)-1.78
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS1.29
BVpS4.96
TBVpS4.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.39%
ROE -18.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.98%
FCFM N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 949.68%
Cap/Sales 14.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.66
Quick Ratio 7.61
Altman-Z 4.46
F-Score5
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)352.72%
Cap/Depr(5y)301.63%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y10.61%
EPS Next 2Y25%
EPS Next 3Y31.09%
EPS Next 5Y27.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year27.25%
Revenue Next 2Y44.13%
Revenue Next 3Y47.77%
Revenue Next 5Y41.2%
EBIT growth 1Y-5.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.75%
EBIT Next 3Y27.24%
EBIT Next 5YN/A
FCF growth 1Y33.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.81%
OCF growth 3YN/A
OCF growth 5YN/A